FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

Chiara Cremolini, Alfredo Falcone, Gabriella Fontanini et al.|The Lancet Oncology|2015

Cited by 1.1k